Skip to main content
All lobbying clients

TRIS PHARMA, INC. AND ITS WHOLLY OWNED SUBSIDIARY ADNEURIS THERAPEUTICS

Lobbying client · New Jersey · filed 2025 to 2026

Biopharmaceutical company.

$350,000 Reported spend
7 Filings counted
1 Outside firm hired
2 Bills named

Spend is reported income plus in-house expenses across 7 filings. Everything on this page comes from one LDA client record (60968), filed by the registrant listed below. These filings have also been reported as TRIS PHARMA, INC. AND ITS WHOLLY OWNED SUBSIDIARY ADNEURIS THERAPEUTICS FKA TRIS.

 Who filed for this client 1
  • AEGIS LLC $350,000 Outside firm · 7 filings

Spend per registrant: fees an outside firm reported, or the costs the client reported for lobbying in-house. The rows add up to the total above.

 Bills named in these filings 2
  • H.R. 1227
    Alternatives to PAIN Act
    7 filings
  • S. 475
    Alternatives to PAIN Act
    7 filings
 Reported by year 2 years
  • 2026 $150,000 3 filings
  • 2025 $200,000 4 filings
 Issues lobbied 1

The count is how many filings named that issue area. A filing reports one lump figure covering every issue on it, so the money above cannot be split between them.

 Agencies and chambers lobbied 3
  • HOUSE OF REPRESENTATIVES 7
  • SENATE 7
  • Natl Highway Traffic Safety Administration (NHTSA) 3

Filings through , the newest posted date on this record. Source: federal Lobbying Disclosure Act filings, synced daily. Money is self-reported by the filer and often rounded. Lobbying is legal, disclosed activity.

Report a problem